Pharmacological Tools for Lysophospholipid GPCRs: Development of Agonists and Antagonists for LPA and S1P Receptors

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2010 Aug 24

PMID 20729877

Citations 22

Authors

Dong-Soon Im

Affiliations

Soon will be listed here.

Abstract

Previous studies on lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) using various approaches have shown that both the molecules can act as intercellular signaling molecules. The discovery of the Edg subfamily of G-protein-coupled receptors (GPCRs) (later renamed LPA(1-3) and S1P(1-5)) for these molecules has opened up a new avenue for pathophysiological research on lysophospholipids. Genetic and molecular studies on lysophospholipid GPCRs have elucidated pathophysiological impacts and roles in cellular signaling pathways. Recently, lysophospholipid GPCR genes have been used to develop receptor subtype-selective agonists and antagonists. The discovery of FTY720, a novel immune modulator, along with other chemical tools, has provided a means of elucidating the functions of each lysophospholipid GPCR on an organ and the whole body level. This communication attempts to retrospectively review the development of agonists and antagonists for lysophospholipid GPCRs, provide integrated information on pharmacological tools for lysophospholipid GPCR signaling, and speculate on future drug development.

Citing Articles

Synthesis and Biological Evaluation of Lysophosphatidic Acid Analogues Using Conformational Restriction and Bioisosteric Replacement Strategies.

Abdelwahid M, Ohsawa K, Uwamizu A, Kano K, Aoki J, Doi T ACS Omega. 2024; 8(51):49278-49288.

PMID: 38162765 PMC: 10753746. DOI: 10.1021/acsomega.3c07668.

gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers.

Wang S, Chen J, Guo X World J Gastrointest Oncol. 2022; 14(8):1388-1405.

PMID: 36160748 PMC: 9412925. DOI: 10.4251/wjgo.v14.i8.1388.

The Emerging Role of Rab5 in Membrane Receptor Trafficking and Signaling Pathways.

Yuan W, Song C Biochem Res Int. 2020; 2020:4186308.

PMID: 32104603 PMC: 7036122. DOI: 10.1155/2020/4186308.

S1P receptor phosphorylation, internalization, and interaction with Rab proteins: effects of sphingosine 1-phosphate, FTY720-P, phorbol esters, and paroxetine.

Martinez-Morales J, Romero-Avila M, Reyes-Cruz G, Garcia-Sainz J Biosci Rep. 2018; 38(6).

PMID: 30366961 PMC: 6294635. DOI: 10.1042/BSR20181612.

Sphingosine-1-Phosphate Receptor 1, Expressed in Myeloid Cells, Slows Diet-Induced Atherosclerosis and Protects against Macrophage Apoptosis in Ldlr KO Mice.

Gonzalez L, Qian A, Tahir U, Yu P, Trigatti B Int J Mol Sci. 2017; 18(12).

PMID: 29244772 PMC: 5751322. DOI: 10.3390/ijms18122721.

References

Simon M, Chap H, DOUSTE-BLAZY L . Human platelet aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: a new group of phospholipid mediators?. Biochem Biophys Res Commun. 1982; 108(4):1743-50. DOI: 10.1016/s0006-291x(82)80113-7. View

Chun J, Goetzl E, Hla T, Igarashi Y, Lynch K, Moolenaar W . International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2002; 54(2):265-9. DOI: 10.1124/pr.54.2.265. View

Lynch K, Macdonald T . Structure-activity relationships of lysophosphatidic acid analogs. Biochim Biophys Acta. 2002; 1582(1-3):289-94. DOI: 10.1016/s1388-1981(02)00183-x. View

Lee C, Rivera R, Dubin A, Chun J . LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem. 2006; 282(7):4310-4317. DOI: 10.1074/jbc.M610826200. View

Proll M, Clark R . Potent Gi-mediated inhibition of adenylyl cyclase by a phosphonate analog of monooleylphosphatidate. Mol Pharmacol. 1991; 39(6):740-4. View

Olivera A, Spiegel S . Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 1993; 365(6446):557-60. DOI: 10.1038/365557a0. View

Caballero S, Swaney J, Moreno K, Afzal A, Kielczewski J, Stoller G . Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res. 2008; 88(3):367-77. PMC: 3756152. DOI: 10.1016/j.exer.2008.07.012. View

Van Brocklyn J, Graler M, Bernhardt G, Hobson J, Lipp M, Spiegel S . Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood. 2001; 95(8):2624-9. View

Kotarsky K, Boketoft A, Bristulf J, Nilsson N, Norberg A, Hansson S . Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther. 2006; 318(2):619-28. DOI: 10.1124/jpet.105.098848. View

10.

Candelore M, Wright M, Tota L, Milligan J, Shei G, Bergstrom J . Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun. 2002; 297(3):600-6. DOI: 10.1016/s0006-291x(02)02237-4. View

11.

Santos W, Heasley B, Jarosz R, Carter K, Lynch K, Macdonald T . Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett. 2004; 14(13):3473-6. DOI: 10.1016/j.bmcl.2004.04.061. View

12.

Kim K, Kim Y, Sacket S, Kim H, Han M, Park D . Sphingosine 1-phosphate (S1P) induces shape change in rat C6 glioma cells through the S1P2 receptor: development of an agonist for S1P receptors. J Pharm Pharmacol. 2007; 59(7):1035-41. DOI: 10.1211/jpp.59.7.0017. View

13.

Yanagida K, Ishii S, Hamano F, Noguchi K, Shimizu T . LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem. 2006; 282(8):5814-24. DOI: 10.1074/jbc.M610767200. View

14.

Zhang H, Desai N, Olivera A, Seki T, Brooker G, Spiegel S . Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol. 1991; 114(1):155-67. PMC: 2289065. DOI: 10.1083/jcb.114.1.155. View

15.

Im D, Clemens J, Macdonald T, Lynch K . Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P5 (Edg-8): structure-activity relationship of sphingosine1-phosphate receptors. Biochemistry. 2001; 40(46):14053-60. DOI: 10.1021/bi011606i. View

16.

Lee C, Rivera R, Gardell S, Dubin A, Chun J . GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem. 2006; 281(33):23589-97. DOI: 10.1074/jbc.M603670200. View

17.

Xu Y, Qian L, Prestwich G . Synthesis of monofluorinated analogues of lysophosphatidic acid. J Org Chem. 2003; 68(13):5320-30. DOI: 10.1021/jo020729l. View

18.

Fells J, Tsukahara R, Liu J, Tigyi G, Parrill A . Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem. 2009; 17(21):7457-64. PMC: 2771199. DOI: 10.1016/j.bmc.2009.09.022. View

19.

Hooks S, Santos W, Im D, Heise C, Macdonald T, Lynch K . Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J Biol Chem. 2000; 276(7):4611-21. DOI: 10.1074/jbc.M007782200. View

20.

Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y . Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem. 2009; 284(26):17731-41. PMC: 2719412. DOI: 10.1074/jbc.M808506200. View